清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes

医学 恶化 呼出气一氧化氮 哮喘 哮喘恶化 嗜酸性粒细胞 内科学 免疫学 队列 肺活量测定
作者
P. Jane McDowell,John Busby,Catherine E. Hanratty,Ratko Djukanović,Ashley Woodcock,Samantha Walker,Timothy C. Hardman,Joseph R. Arron,David F. Choy,Peter Bradding,Christopher Brightling,Rekha Chaudhuri,Douglas C. Cowan,Adel Mansur,Stephen J. Fowler,Sarah Diver,Peter Howarth,James Lordan,Andrew Menzies‐Gow,Timothy Harrison,Douglas S. Robinson,Cécile Holweg,John G. Matthews,Ian D. Pavord,Liam G. Heaney
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:206 (5): 545-553 被引量:24
标识
DOI:10.1164/rccm.202201-0129oc
摘要

Rationale: The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although present in a minority of patients with severe asthma, very little is known about the mechanisms underlying T2-low asthma, making it a significant unmet need in asthma research. Objectives: The objective of this study was to explore the differences between study exacerbators and nonexacerbators, to describe physiological changes at exacerbation in those who are T2HIGH and T2LOW at the time of exacerbation, and to evaluate the stability of inflammatory phenotypes when stable and at exacerbation. Methods: Exacerbation assessment was a prespecified secondary analysis of data from a 48-week, multicenter, randomized controlled clinical study comparing the use of biomarkers and symptoms to adjust steroid treatment in a T2-low severe asthma–enriched cohort. Participants were phenotyped as T2LOW (fractional exhaled nitric oxide ⩽ 20 ppb and blood eosinophil count ⩽ 150 cells/µl) or T2HIGH (fractional exhaled nitric oxide > 20 or blood eosinophil count > 150) at study enrollment and at each exacerbation. Here, we report the findings of the exacerbation analyses, including comparison of exacerbators and nonexacerbators, the physiological changes at exacerbation in those who had evidence of T2 biology at exacerbation versus those that did not, and the stability of inflammatory phenotypes when stable and at exacerbation. Measurements and Main Results: Of the 301 participants, 60.8% (183) had one or more self-reported exacerbations (total of 390). Exacerbators were more likely to be female, have a higher body mass index, and have more exacerbations requiring oral corticosteroid and unscheduled primary care attendances for exacerbations. At enrollment, 23.6% (71) were T2LOW and 76.4% (230) T2HIGH. The T2LOW group had more asthma primary care attendances, were more likely to have a previous admission to HDU (high dependency unit)/ICU and to be receiving maintenance oral corticosteroids. At exacerbation, the T2LOW events were indistinguishable from T2HIGH exacerbations in terms of lung function (mean fall in T2LOW FEV1, 200 [400] ml vs. T2HIGH 200 [300] ml; P = 0.93) and symptom increase (ACQ5: T2LOW, 1.4 [0.8] vs. T2HIGH, 1.3 [0.8]; P = 0.72), with no increase in T2 biomarkers from stable to exacerbation state in the T2LOW exacerbations. The inflammatory phenotype within individual patients was dynamic; inflammatory phenotype at study entry did not have a significant association with exacerbation phenotype. Conclusions: Asthma exacerbations demonstrating a T2LOW phenotype were physiologically and symptomatically similar to T2HIGH exacerbations. T2LOW asthma was an unstable phenotype, suggesting that exacerbation phenotyping should occur at the time of exacerbation. The clinically significant exacerbations in participants without evidence of T2 biology at the time of exacerbation highlight the unmet and pressing need to further understand the mechanisms at play in non-T2 asthma. Clinical trial registered with www.clinicaltrials.gov (NCT02717689).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜应助ceeray23采纳,获得20
9秒前
41秒前
Able完成签到,获得积分10
42秒前
我是笨蛋完成签到 ,获得积分10
45秒前
ceeray23发布了新的文献求助20
47秒前
Owen应助董可以采纳,获得10
59秒前
酷酷妙梦完成签到,获得积分10
1分钟前
科研通AI2S应助彦嘉采纳,获得10
1分钟前
小二郎应助科研通管家采纳,获得10
1分钟前
hhh2018687完成签到,获得积分10
1分钟前
科研通AI2S应助ceeray23采纳,获得20
2分钟前
忘忧Aquarius完成签到,获得积分10
2分钟前
wujiwuhui完成签到 ,获得积分10
2分钟前
Lny发布了新的文献求助30
2分钟前
sh1ro完成签到,获得积分10
2分钟前
luang应助ceeray23采纳,获得40
2分钟前
3分钟前
ww完成签到,获得积分10
3分钟前
斯文败类应助ceeray23采纳,获得20
3分钟前
机智秋莲发布了新的文献求助20
3分钟前
ChatGPT完成签到,获得积分10
3分钟前
所所应助科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
ceeray23发布了新的文献求助20
4分钟前
海阔天空完成签到 ,获得积分10
4分钟前
zys发布了新的文献求助10
4分钟前
ffdhdh应助LYZSh采纳,获得10
4分钟前
5分钟前
机智秋莲完成签到,获得积分20
5分钟前
欣欣子完成签到 ,获得积分10
5分钟前
apt完成签到 ,获得积分10
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
6分钟前
董可以发布了新的文献求助10
6分钟前
Orange应助董可以采纳,获得10
6分钟前
飞翔的企鹅完成签到,获得积分10
7分钟前
7分钟前
董可以发布了新的文献求助10
7分钟前
LYZSh发布了新的文献求助10
7分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990543
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234